Merck to buy biopharmaceutical firm OncoImmune for $425m

This article was originally published here

Under the deal, OncoImmune shareholders will be eligible to secure sales-based payments and payments contingent on the achievement of certain regulatory milestones. Recently, the biopharmaceutical company announced positive

The post Merck to buy biopharmaceutical firm OncoImmune for $425m appeared first on Pharmaceutical Business review.